Clinical glycoproteomics and artificial intelligence

A powerful new tool for precision medicine

InterVenn Biosciences has developed a proprietary glycoproteomic platform based on AI and mass spectrometry for the discovery of novel glycoproteomic biomarkers and their application to next-gen precision medicine.

The company is working to find new solutions in a range of oncology indications, along with making its Vista suite of solutions available to its partners for advanced life-science R&D applications.

InterVenn’s VISTA^TM is the first commercially available platform that can assess (serum or plasma) protein glycosylation in a site-specific manner, across thousands of peptides and glycopeptides.